Investigation of the Effect of Food on the Bioavailability of a 25 mg Empagliflozin Tablet and Assessment of Dose Proportionality Between 10 mg and 25 mg Empagliflozin Tablets in an Open, Randomised, Single Dose, Three-period Cross-over Study in Healthy Male and Female Subjects.
Phase of Trial: Phase I
Latest Information Update: 02 Sep 2014
At a glance
- Drugs Empagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 14 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Oct 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 18 Oct 2011 New trial record